Guilford licensed a novel class of potential drugs to Pfizer. The exclusive deal covers NAALADse inhibitors useful for treating neurodegenerative disorders including Huntington’s disease, diabetic neuropathy and neuropathic pain. Guilford will receive US$77 M, if just one drug is commercialized with an additional indication.